Convergence Investment Partners LLC Has $2.43 Million Stock Position in Halozyme Therapeutics, Inc. $HALO

Convergence Investment Partners LLC boosted its holdings in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO) by 21.9% in the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 37,599 shares of the biopharmaceutical company’s stock after purchasing an additional 6,748 shares during the period. Convergence Investment Partners LLC’s holdings in Halozyme Therapeutics were worth $2,430,000 at the end of the most recent quarter.

Other large investors have also recently modified their holdings of the company. Norges Bank acquired a new position in shares of Halozyme Therapeutics during the 4th quarter worth $128,201,000. William Blair Investment Management LLC acquired a new stake in Halozyme Therapeutics in the fourth quarter valued at about $124,031,000. Voloridge Investment Management LLC bought a new position in Halozyme Therapeutics in the third quarter valued at about $77,587,000. Qube Research & Technologies Ltd bought a new position in Halozyme Therapeutics in the second quarter valued at about $51,295,000. Finally, Mizuho Markets Americas LLC raised its stake in Halozyme Therapeutics by 270.8% during the fourth quarter. Mizuho Markets Americas LLC now owns 1,268,673 shares of the biopharmaceutical company’s stock worth $85,382,000 after acquiring an additional 926,526 shares in the last quarter. Institutional investors and hedge funds own 97.79% of the company’s stock.

Halozyme Therapeutics Stock Down 0.9%

NASDAQ:HALO opened at $77.09 on Tuesday. Halozyme Therapeutics, Inc. has a one year low of $55.64 and a one year high of $82.26. The company has a debt-to-equity ratio of 8.81, a current ratio of 2.76 and a quick ratio of 2.33. The company has a market cap of $9.14 billion, a PE ratio of 27.73, a P/E/G ratio of 0.32 and a beta of 0.84. The firm’s 50 day simple moving average is $72.25 and its 200 day simple moving average is $70.27.

Halozyme Therapeutics (NASDAQ:HALO) last announced its quarterly earnings results on Monday, May 11th. The biopharmaceutical company reported $1.60 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.54 by $0.06. The firm had revenue of $376.71 million during the quarter, compared to analysts’ expectations of $358.60 million. Halozyme Therapeutics had a net margin of 23.13% and a return on equity of 187.91%. The company’s revenue was up 42.2% on a year-over-year basis. During the same period in the prior year, the company posted $1.11 EPS. Halozyme Therapeutics has set its FY 2026 guidance at 7.750-8.250 EPS. On average, research analysts anticipate that Halozyme Therapeutics, Inc. will post 7.54 earnings per share for the current year.

Insider Activity at Halozyme Therapeutics

In related news, CEO Helen Torley sold 1,923 shares of the firm’s stock in a transaction on Wednesday, July 8th. The stock was sold at an average price of $79.77, for a total transaction of $153,397.71. Following the completion of the transaction, the chief executive officer directly owned 767,780 shares of the company’s stock, valued at $61,245,810.60. This trade represents a 0.25% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Mahesh Krishnan sold 7,304 shares of Halozyme Therapeutics stock in a transaction dated Monday, June 29th. The stock was sold at an average price of $75.00, for a total value of $547,800.00. Following the transaction, the director directly owned 14,462 shares in the company, valued at $1,084,650. The trade was a 33.56% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 74,102 shares of company stock worth $5,205,798 over the last three months. Company insiders own 2.50% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities research analysts have recently weighed in on HALO shares. HC Wainwright restated a “buy” rating on shares of Halozyme Therapeutics in a research note on Tuesday, June 16th. Benchmark reissued a “buy” rating on shares of Halozyme Therapeutics in a research note on Wednesday, June 3rd. Weiss Ratings raised shares of Halozyme Therapeutics from a “hold (c)” rating to a “buy (b-)” rating in a research note on Tuesday, May 12th. Morgan Stanley cut their target price on shares of Halozyme Therapeutics from $96.00 to $93.00 and set an “overweight” rating on the stock in a research report on Tuesday, May 12th. Finally, Wall Street Zen raised shares of Halozyme Therapeutics from a “hold” rating to a “buy” rating in a research note on Saturday, May 16th. Eight analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $81.60.

About Halozyme Therapeutics

Halozyme Therapeutics, Inc is a biopharmaceutical company headquartered in San Diego, California, that specializes in the development and commercialization of novel drug-delivery technologies. Founded in 1998, Halozyme focuses on enabling subcutaneous administration of biologic therapies through its proprietary platforms. The company’s core mission is to improve patient access and convenience while maintaining efficacy and safety profiles comparable to or better than traditional routes of administration.

The company’s flagship technology, ENHANZE®, is based on recombinant human hyaluronidase PH20 (rHuPH20), an enzyme that transiently degrades hyaluronan in the extracellular matrix.